PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2022-09-07

Date Title Company
07-Sep-2022 KITE’S CAR T-CELL THERAPY TECARTUS® (BREXUCABTAGENE AUTOLEUCEL) GRANTED EUROPEAN MARKETING AUTHORISATION FOR THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (r/r ALL) KITE’S
07-Sep-2022 Peripheral Vascular Stents Market Revenue Growth And Forecast 2028 MARKITWIRED
07-Sep-2022 Pigmented Lesion Treatment Market Report Overview 2017, Industry Size, Top Leading Manufacturers with Share 2022 MARKITWIRED
07-Sep-2022 Zika Virus Testing Market Analysis, Size, Share, Opportunities and Forecast To 2031 |Future Market Insights MARKITWIRED
07-Sep-2022 Animal Model Market Future Demands, Regional Developments and Industry Competitive Landscape Analysis 2028 MARKITWIRED
07-Sep-2022 Insulin Delivery Pens Market by Competitive Landscape, SWOT Analysis, Opportunities and Challenges, Growth by 2017 to 2027 MARKITWIRED
07-Sep-2022 First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s) Businesswire
07-Sep-2022 BRAIN TUMOR: ANTI EPILEPTIC DRUG PROMISING & TOLERABLE St. Pölten/Krems
07-Sep-2022 Radiology technology start-up Hexarad raises further £2.2m to complete Series A funding Radiology technology
07-Sep-2022 Almac Sciences and UCD strengthen collaboration with prestigious SFI grant Almac Sciences
07-Sep-2022 Press Release Media Contacts: IB Communications Tel +44 (0)20 89434685 immutep@ibcomms.agency Immutep announces investigator-initiated Phase II trial evaluating LAG-3 candidate eftilagimod alpha (efti) in soft tissue sarcoma Immutep
07-Sep-2022 Dizlin Pharmaceuticals publishes data from pharmacokinetic study (PK) (IPO-001) with Infudopa SubC (DIZ102) and Infudopa IntraV (DIZ101) in Neurology Dizlin Pharmaceuticals AB
07-Sep-2022 LYNPARZA (olaparib) APPROVED IN GREAT BRITAIN AS ADJUVANT TREATMENT FOR PATIENTS WITH GERMLINE BRCA-MUTATED HER2-NEGATIVE HIGH-RISK EARLY BREAST CANCER AstraZeneca
07-Sep-2022 Brainomix and Bridge Biotherapeutics, Inc. Announce Partnership to Utilize Brainomix’ AI-Powered e-ILD Software for Automated Assessment of Idiopathic Pulmonary Fibrosis (IPF) Brainomix and Bridge Biotherapeutics
07-Sep-2022 mdgroup Chief Operating Officer LaQuinta Jernigan Honoured as one of 100 Most Inspiring People in Life Sciences 2022 mdgroup
07-Sep-2022 Brainomix and Bridge Biotherapeutics, Inc. Announce Partnership to Utilize Brainomix’ AI-Powered e-ILD Software for Automated Assessment of Idiopathic Pulmonary Fibrosis (IPF) Brainomix and Bridge Biotherapeutics, Inc.
07-Sep-2022 STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer STORM
07-Sep-2022 Aqilion has completed a rights issue AQILION AB
07-Sep-2022 Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Granted Marketing Authorization by European Commission for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome Rhythm Pharmaceuticals, Inc
07-Sep-2022 LYNPARZA (olaparib) APPROVED IN GREAT BRITAIN AS ADJUVANT TREATMENT FOR PATIENTS WITH GERMLINE BRCA-MUTATED HER2-NEGATIVE HIGH-RISK EARLY BREAST CANCER AstraZeneca